ArticleBMJ public health2026
Adoption of universal prenatal syphilis rescreening recommendations across Ontario, Canada: a difference-in-differences analysis.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Congenital syphilis rates increased sharply in Ontario, Canada, between 2018 and 2023, underscoring gaps in prenatal prevention. In response, public health units (PHUs) expanded recommendations for routine repeat syphilis screening (rescreening) during pregnancy. We examined the adoption and implementation of these rescreening recommendations and assessed their impact on prenatal syphilis screening rates. Methods: We conducted an environmental scan of all Ontario PHUs to identify changes to local recommendations and implementation strategies for prenatal syphilis screening between 2018 and 2023. Based on this scan, we identified nine sociodemographically comparable PHUs: four that adopted universal rescreening recommendations (intervention), and five that did not modify recommendations (control). We leveraged this variation using a difference-in-differences analysis to evaluate whether local public health recommendations were associated with changes in prenatal syphilis screening rates. Results: 28 PHUs (82%) responded to the survey, representing all of Ontario's health regions. Prenatal syphilis screening recommendations varied over time and between PHUs. By December 2023, 36% (n=10) recommended rescreening for syphilis at mid-gestation and/or at delivery. The primary drivers of adopting rescreening recommendations included changes in local (n=9; 90%), provincial (n=8; 80%) and national (n=9; 90%) syphilis epidemiology. A total of 58 103 prenatal syphilis tests (28 887 from intervention PHUs and 29 216 from control) were analysed. Accounting for multiple intervention groups and staggered adoption, universal rescreening recommendations were associated with an average of 375 more tests per 1000 pregnancies per month (95% CI 321 to 430) across intervention PHUs. The effect varied by PHU, reflecting differences in local implementation strategies and contexts. Conclusions: Repeat screening recommendations were associated with an increase in prenatal syphilis screening; however, inconsistent implementation between PHUs highlights the challenges of translating public health policies into clinical practice. Co-ordinated implementation strategies are essential to ensure equitable access to timely screening for all pregnant people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.